FC
ONCY

Financial Consulate’s Oncolytics Biotech ONCY Stock Holding History

Financial Consulate’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-41,474
Closed -$78K – 103
2020
Q2 		$78K Buy
+41,474
New +$78.1K 0.04% 98

Other funds holding ONCY

Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return

Financial Consulate's ONCY Position: Q3 2020 in Review

Financial Consulate sold out of Oncolytics Biotech (ONCY) in Q3 2020, closing a stake of 41,474 shares — an estimated $78K sold.

Financial Consulate first reported a position in ONCY in Q2 2020 and held it in 1 quarter. The position peaked at $78K in Q2 2020. 36 funds tracked by Wall St. Rank hold ONCY as of Q3 2020.

  • Financial Consulate reported no remaining Oncolytics Biotech position as of Q3 2020 after selling out during the quarter.
  • Financial Consulate sold 41,474 Oncolytics Biotech shares in Q3 2020, an estimated $78K.
  • Financial Consulate first reported a position in Oncolytics Biotech in Q2 2020 and held it in 1 quarter.
  • Financial Consulate's Oncolytics Biotech position peaked at $78K in Q2 2020.
  • 36 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q3 2020.

Based on Financial Consulate's 13F filing for Q3 2020, filed 20 Oct 2020.